Case Studies in Optimal Management of Invasive Candidiasis
September 12, 2023
September 11, 2024
This activity is jointly provided by PACE; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
This activity is supported by an independent educational grant from Melinta Therapeutics.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Pharmacists — 1.5 Contact Hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education
All other healthcare professionals completing this course will be issued a statement of participation.
This initiative is directed to infectious diseases physicians, critical care physicians, hospitalists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other health care providers responsible for the management of invasive candidiasis.
This multimedia CME/CPE enduring activity from the live MSGERC Town Hall held on July 7, 2023, discusses the newest trends in the management of invasive candidiasis. The expert faculty discuss hospital and health care-associated infection scenarios: a patient coming in from a long-term acute care hospital (LTACH), an invasive fungal infection in a stem cell transplant patient, and an intra-abdominal infection in a hospitalized surgical patient.
Upon completion of this activity, participants should be better able to:
- Identify patients at risk for invasive candidiasis
- Employ appropriate diagnostic tools for invasive candidiasis
- Select appropriate antifungal therapy for patients with invasive candidiasis using antifungal stewardship principles
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ (Chairperson)
Professor of Medicine and Epidemiology
Memorial Hermann Endowed Chair
Vice Chair of Medicine for Healthcare Quality
Chief, Division of Infectious Diseases
McGovern Medical School
Peter G. Pappas, MD, FACP (Chairperson)
Emeritus Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Alabama School of Medicine
Principal Investigator, Mycoses Study Group
Jennifer Cuellar-Rodriguez, MD
Director, Transplant Infectious Diseases Consult Service
Laboratory of Clinical Immunology and Microbiology
Division of Intramural Research
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Jose Vazquez, MD, FACP, FIDSA
Division Chief and Professor of Medicine
Infectious Diseases at Augusta University
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE); Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008073-9999-23-184-H01-P
Type of Activity: Knowledge
Disclosures of Conflicts of Interest
- Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ
- GRANT/RESEARCH SUPPORT: Astellas, Gilead, Pfizer, Pulmocide, Scynexis , T2Biosystems
- CONSULTANT/ADVISORY BOARD: Cidara, F2G, GSK, Pfizer, Viractor, Melinta
Jennifer Cuellar-Rodriguez, MD, has nothing to disclose.
- Peter Pappas, MD, FACP
- GRANT/RESEARCH SUPPORT: Melinta, Scynexis
- CONSULTANT/ADVISORY BOARD: F2G, Matinas
- Jose Vazquez, MD, FACP, FIDSA
- GRANT/RESEARCH SUPPORT: Scynexis
- CONSULTANT/ADVISORY BOARD: Cidara, F2G
Managers and Planning Committee Disclosures
Lisa A. Tushla, PhD, H(ASCP) of Terranova Medica, LLC discloses research support from Bristol Myers Squibb and Novartis. Ava Duffy has no relevant financial relationship(s) to disclose with ineligible companies. The MSGERC and PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. Participation in this self-study activity should be completed in approximately 1.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from September 12, 2023 through September 11, 2024:If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity quiz(zes)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-assessment, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For CME questions please contact: [email protected].